ABSTRACT
The new allele A*02:355 differs from A* 02:03:01 at positions 98 (TâA) and 102(AâC) resulting in an amino acid exchange F9âT. Interallelic sequence exchange is more likely the mechanism of its origination. The amino acid replacement influences the HLA peptide binding cleft and might have significant functional effects.
Subject(s)
Alleles , Amino Acid Substitution , HLA-A2 Antigen/genetics , Mutation , Asian People , Base Sequence , Exons , Gene Expression , HLA-A2 Antigen/immunology , Hematopoietic Stem Cell Transplantation , Histocompatibility Testing , Humans , Sequence Analysis, DNA , Tissue DonorsABSTRACT
DRB1*15:66:02 differs from DRB1*15:66:01 at codons 57 and 58 resulting in no coding change.
Subject(s)
Alleles , HLA-DRB1 Chains/genetics , Hematopoietic Stem Cells/immunology , Polymorphism, Single Nucleotide , Silent Mutation , Asian People , Base Sequence , Codon , Exons , Gene Expression , Genetic Loci , HLA-DRB1 Chains/immunology , Hematopoietic Stem Cell Transplantation , Hematopoietic Stem Cells/cytology , Histocompatibility Testing , Humans , Molecular Sequence Data , Sequence Alignment , Sequence Analysis, DNA , Tissue DonorsABSTRACT
The anticancer efficacy of the new anticancer tripeptide, L-proline-m-bis (2-chloroethyl) amino-L-phenylalanyl-L-norvaline ethyl ester hydrochloride (MF13), was investigated in mice. MF13 showed a therapeutic effect in liquid tumors and induced complete remission even in late stage malignancies. MF13 also inhibited human colon cancer growth in nude mice by more than 85% (volume, p<0.001). It acted in a dose-dependent manner and induced a complete regression of tumor in 20% of the mice when the initial dose was high (15 mg/kg, i.p.). Human melanoma exhibited a response to MF13 similar to colon cancer. Activity of MF13 in murine hepatoma in vivo was stronger than its precursor m-sarcolysin (p<0.001). Tumor cells in peritoneal cavities of the MF13 treated (s.c.) mice underwent an irreversible apoptosis. Side effects of MF13 were the transient depression of hemopoiesis and loss of body weight, which vanished within 9-10 days. LD50 of MF13 of a single i.p. injection was 27 mg/kg (94 mg/m2), 11 times higher than the therapeutic dose of a single injection.